未登录

J

Jean M. Bidlack

University of Rochester

H指数:41

被引数:5,376

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimization of the Macrocyclic Tetrapeptide [D-Trp]CJ-15,208 to Prevent Stress-Induced Relapse of Cocaine-Seeking Behavior

[优化大环四肽[D-Trp]CJ-15,208以预防压力诱导的可卡因寻求行为的复发]

Molecules 2025, Vol. 30, Page 3993

IF4.6

2025-10-050

OAAI

Mu Opioid Receptor Positive Allosteric Modulator BMS-986122 Confers Agonist-Dependent G Protein Subtype Signaling Bias

Mu阿片受体正向别构调节剂BMS-986122表现出激动剂依赖的G蛋白亚型信号偏向。

IF3

2025-05-160

OA

The Neuroimmune Pharmacology of SARS-CoV-2

JOURNAL OF NEUROIMMUNE PHARMACOLOGY

IF3.5

2021-12-220

OAAI

The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings

JOURNAL OF NEUROIMMUNE PHARMACOLOGY

IF3.5

2021-11-261

OAAI

Society on NeuroImmune Pharmacology COVID-19 Virtual Workshop

JOURNAL OF NEUROIMMUNE PHARMACOLOGY

IF3.5

2021-06-282

OAAI

Deciphering the Novel Role of Gaz in Mu Opioid Receptor Signaling

IF4.2

2021-05-140

PRE

Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through Gαz as Shown with Bioluminescence Resonance Energy Tranfer

MOLECULAR PHARMACOLOGY

IF3

2020-10-016

OAAI

Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration

PSYCHOPHARMACOLOGY

IF3.3

2020-01-079

OAAI

In vitro characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment for major depressive disorder

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2019-01-010

PREAI

In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2018-11-0154

OAAI

ALKS 5461: Affinity, Potency, and Functional Activity of Buprenorphine and Samidorphan Alone and in Combination

BIOLOGICAL PSYCHIATRY

IF9

2018-05-010

PREAI

Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model

BRAIN BEHAVIOR AND IMMUNITY

IF7.6

2018-01-0115

PREAI

Structural Requirements for CNS Active Opioid Glycopeptides

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2015-07-2314

PREAI

Can Amphipathic Helices Influence the CNS Antinociceptive Activity of Glycopeptides Related to β-Endorphin?

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2014-03-0715

OAAI

Preliminary Pharmacological Evaluation of Enantiomeric Morphinans

ACS CHEMICAL NEUROSCIENCE

IF3.9

2014-01-0818

OA

Synthesis and Pharmacological Evaluation of Aminothiazolomorphinans at the Mu and Kappa Opioid Receptors

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2013-10-2917

OA

Cyclazocine Revisited

NEUROCHEMICAL RESEARCH

IF3.8

2013-03-2167

PREAI

Synthesis, Binding Affinity, and Functional in Vitro Activity of 3-Benzylaminomorphinan and 3-Benzylaminomorphine Ligands at Opioid Receptors

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2012-04-0411

OA

Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins

FUTURE MEDICINAL CHEMISTRY

IF3.4

2012-02-0342

OAAI

Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

IF2.5

2012-01-0114

PREAI